Is this you? Create Your Porfile
Avatar

Cleo Connolly

Pfizer

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Cleo Connolly is active.

Explore More

Publication

Featured researches published by Cleo Connolly.

Bioorganic & Medicinal Chemistry Letters | 1997

discovery and structure-activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors

Cleo Connolly; James Marino Hamby; Mel Conrad Schroeder; Mark Robert Barvian; Gina H. Lu; Robert L. Panek; Aneesa M. Amar; Cindy Shen; Alan J. Kraker; David W. Fry; Wayne D. Klohs; Annette Marian Doherty

Abstract The inhibition of tyrosine kinase-mediated signal transduction pathways represents a therapeutic approach to the intervention of proliferative diseases such as cancer, atherosclerosis, and restenosis. A novel series of pyrido[2,3-d]pyrimidine inhibitors of the PDGFr, bFGFr, and c-Src tyrosine kinases was developed from compound library screening and lead optimization.1 In addition, highly selective inhibitors of the FGFr tyrosine kinase were also discovered and developed from this novel series of pyrido[2,3-d]pyrimidines. The syntheses, biological evaluation, and structure-activity relationships of this series are reported.

Journal of Medicinal Chemistry | 1992

Structure-activity relationships of a series of 2-amino-4-thiazole-containing renin inhibitors

William Chester Patt; Harriet W. Hamilton; Michael Douglas Taylor; Michael J. Ryan; David G. Taylor; Cleo Connolly; Annette M. Doherty; Sylvester R. Klutchko; Ila Sircar

Journal of Medicinal Chemistry | 1991

Synthesis and structure-activity relationships of a novel series of non-peptide angiotensin II receptor binding inhibitors specific for the AT2 subtype.

C. John Blankley; John C. Hodges; Sylvester Klutchko; Richard J. Himmelsbach; Alexander Chucholowski; Cleo Connolly; Sandra J. Neergaard; Michael S. Van Nieuwenhze; Alan Sebastian

Journal of Medicinal Chemistry | 1997

Structure−Activity Relationships for a Novel Series of Pyrido[2,3-d]pyrimidine Tyrosine Kinase Inhibitors

James M. Hamby; Cleo Connolly; Mel C. Schroeder; R. Thomas Winters; H. D. Hollis Showalter; Robert L. Panek; Terry C. Major; Bronislawa Olsewski; Michael J. Ryan; Tawny K. Dahring; Gina H. Lu; Joan Keiser; Aneesa Amar; Cindy Shen; Alan J. Kraker; Veronika Slintak; James M. Nelson; David W. Fry; Laura Bradford; and Hussein Hallak; Annette M. Doherty

Archive | 1995

6-ARYL PYRIDO[2,3-d]PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION

Clifton John Blankley; Annette Marian Doherty; James Marino Hamby; Robert L. Panek; Mel Conrad Schroeder; Howard Daniel Hollis Showalter; Cleo Connolly

Journal of Pharmacology and Experimental Therapeutics | 1998

In Vitro Biological Characterization and Antiangiogenic Effects of PD 166866, a Selective Inhibitor of the FGF-1 Receptor Tyrosine Kinase

Robert L. Panek; Gina H. Lu; Tawny K. Dahring; Brian L. Batley; Cleo Connolly; James Marino Hamby; Kathryn J. Brown

Journal of Medicinal Chemistry | 2001

Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity

Mel C. Schroeder; James M. Hamby; Cleo Connolly; Patrick J. Grohar; R. Thomas Winters; Mark Robert Barvian; Charles W. Moore; Stacey L. Boushelle; Sheila M. Crean; Alan J. Kraker; Denise L. Driscoll; Patrick W. Vincent; William L. Elliott; Gina H. Lu; Brian L. Batley; Tawny K. Dahring; Terry C. Major; Robert L. Panek; and Annette M. Doherty; H. D. Hollis Showalter

Journal of Medicinal Chemistry | 2000

3-(3,5-Dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and Related 2-Urea Derivatives Are Potent and Selective Inhibitors of the FGF Receptor-1 Tyrosine Kinase

Andrew M. Thompson; Cleo Connolly; James Marino Hamby; Stacey L. Boushelle; Brian G. Hartl; Aneesa M. Amar; Alan J. Kraker; Denise L. Driscoll; Randall W. Steinkampf; Sandra J. Patmore; Patrick W. Vincent; Bill J. Roberts; William L. Elliott; Wayne D. Klohs; Wilbur R. Leopold; H. D. Hollis Showalter; William A. Denny

Bioorganic & Medicinal Chemistry Letters | 2007

Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists

Paul Galatsis; Koji Yamagata; John A. Wendt; Cleo Connolly; John W. Mickelson; Jared Bruce John Milbank; Susan Bove; Christopher S. Knauer; Rachel M. Brooker; Corinne E. Augelli-Szafran; Roy D. Schwarz; Jack J. Kinsora; Kenneth S. Kilgore

Archive | 1998

6-aryl naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation

Clifton John Blankley; Annette Marian Doherty; James Marino Hamby; Robert L. Panek; Mel Conrad Schroeder; Howard Daniel Hollis Showalter; Cleo Connolly

Explore More

Collaboration

Dive into the Cleo Connolly's collaboration.

Top Co-Authors
Avatar

Christopher James Deur

Pfizer

View shared research outputs
Top Co-Authors
Avatar

Alan J. Kraker

Parke-Davis

View shared research outputs
Top Co-Authors
Avatar

Annette M. Doherty

Pfizer

View shared research outputs
Top Co-Authors
Avatar

Chris Limberakis

Pfizer

View shared research outputs
Top Co-Authors
Avatar

Clarke B. Taylor

Pfizer

View shared research outputs
Top Co-Authors
Avatar

Denton Wade Hoyer

Pfizer

View shared research outputs
Top Co-Authors
Avatar

H. D. Hollis Showalter

University of Michigan

View shared research outputs
Top Co-Authors
Avatar

Harriet W. Hamilton

Pfizer

View shared research outputs
Top Co-Authors
Avatar

Tawny K. Dahring

Pfizer

View shared research outputs
Top Co-Authors
Avatar

Gina H. Lu

Parke-Davis

View shared research outputs
Explore More
Researchain Logo
Decentralizing Knowledge